Evaluating Patient Reported Outcomes in Radiation Therapy, The PRO-RT Study

Sponsor
Mayo Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT05224271
Collaborator
National Cancer Institute (NCI) (NIH)
150
1
21.9
6.8

Study Details

Study Description

Brief Summary

This study explores the use of the Hugo platform to involve study participants in their healthcare and treatments. The Hugo platform may allow researchers to collect better and more accurate real-time health data, from other clinics/hospitals, pharmacies and other electronic devices. The purpose of this research is to see if the use of the Hugo platform is consistent, accurate, cost effective, and time efficient, as it collects and transmits important real-time health information from other clinics/hospitals, pharmacies, and other electronic devices.

Condition or Disease Intervention/Treatment Phase
  • Other: Electronic Health Record Review
  • Other: Medical Device Usage and Evaluation
  • Other: Survey Administration

Detailed Description

PRIMARY OBJECTIVES:
  1. Evaluate the data aggregation from a patient centered platform over a follow up period for completeness and quality, including externally linked electronic health record (EHR) information, toxicity completion, and the patient reported outcomes (PRO) response rates for study patients, compared with historical pre-coronavirus disease (COVID) cohort of registry patients.

  2. To explore biometric information obtained from wearables as it pertains to the toxicity of treatment for patients using a wearable device.

  3. To estimate app-based survey completion rates using Hugo-based survey incentive completion (gift cards).

  4. To explore the cost data available on the platform.

OUTLINE:

Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Patient Reported Outcomes in Radiation Therapy (PRO-RT)
Actual Study Start Date :
Mar 2, 2022
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Observational (surveys, medical records & Fitbit collection)

Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.

Other: Electronic Health Record Review
Medical records are collected

Other: Medical Device Usage and Evaluation
Fitbit information is collected

Other: Survey Administration
Complete surveys

Outcome Measures

Primary Outcome Measures

  1. Survey completion rate [Baseline up to 6 months after completion of radiation therapy]

    The difference in rates will be estimated. A chi square, or Fisher's exact test as appropriate, will be used to compare the rates between cohorts. A logistic regression model will be used to understand the association of patient and disease variables with the odds of completion (at least one of the surveys at the treated site).

  2. Percentage of patients with access to wearable device [Up to 6 months after completion of radiation therapy]

    A logistic regression model will be used to understand the association of patient and disease variables with the odds of access to a wearable device.

Secondary Outcome Measures

  1. Incidence of adverse events [Up to 6 months after completion of radiation therapy]

    Logistic regression will be used to predict presence of a patient toxicity. Baseline patient and disease characteristics, along with biometric information will be used to assess associations with toxicity. Multiple variable models will be considered depending on the number of patients identified with a toxicity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18+

  • English speaking

  • Consented for Outcomes Registry Study (15-000136)

  • Undergoing radiotherapy for cancer treatment with curative intent

  • Willing to and able to give consent and participate in study

  • Willing to complete all surveys

  • Able to access a device (computer, smartphone, or tablet) with web access every day to complete study surveys

  • Willing to connect to a device (i.e., a smartphone, Fitbit, or tablet) that can regularly link to Hugo for data transfer

  • Willing to share personal information to Tremendous to be able to obtain the Visa e-cards for time and effort put into this study

  • Willing to use the Hugo health data sharing platform

  • Willing to create a Mayo Clinic Patient Portal (if not already created)

Exclusion Criteria:
  • Unable to give consent and enroll prior to administration of baseline survey

  • Partial breast radiation therapy (RT) (3 fraction), due to overlap in cadence used for all disease sites

  • Stereotactic body radiation therapy (SBRT) to the lung, due to overlap in cadence used for all disease sites

  • Co-enrollment on another PRO related study (soft rule)

  • Coordinator would need to get source data from Adam via Hugo

  • Response data will only be accessible by select people

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Kimberly S Corbin, Mayo Clinic in Rochester

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT05224271
Other Study ID Numbers:
  • ROR2103
  • NCI-2021-12580
  • ROR2103
  • P30CA015083
First Posted:
Feb 4, 2022
Last Update Posted:
Apr 21, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 21, 2022